Pipeline

Boost’s Rapid Antigen Deployment (RAD™) Platform approach turns a new threat into a scale-up--ready vaccine in as little as 10 days. Our lead SARS-CoV-2 program is in Phase 1 as both an intramuscular and an intranasal candidate, with Phase 2 preparations underway.

Additionally, we're advancing assets against seasonal and pandemic influenza, all four Dengue serotypes, Zika, and Japanese encephalitis. Epstein-Barr virus and Norovirus are next in our sights. Other disease targets are also being evaluated with partners.

Every program draws on the same foundational science to rapidly create high-performance proteins, and each new pathogen family is building the company’s capabilities. This is what pandemic-ready looks like: high-performance proteins, at the speed of mRNA.